Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SHR0302 Tablets in Healthy Subjects
NCT06202612Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivarmacitinib in autoimmune diseases (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 5, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 5 and 2 more. Started Jan 2024; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT06202612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202612.